Please assess the completion status of the following clinical trial:

Trial Title: Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* undergoing ambulatory inguinal and/or abdominal surgery amenable to a Transversus Abdominis Plane nerve block (unilateral or bilateral).~* expected postoperative pain to be at least moderate in severity the day following surgery~* age 18 years or older~* desires a regional anesthetic for postoperative analgesia~* is able to understand the possible perineural infusion-related complications, study protocol, and catheter/pump care~* has a caretaker through the first night after surgery~* has an ASA Physical Status Classification of 1-3~Exclusion Criteria:~* any contraindication for a continuous Transversus Abdominis Plane nerve block~* any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.~* current chronic opioid or tramadol use~* history of alcohol or opioid abuse~* know allergy or other contraindication to the study medication~* pregnancy~* known hepatic or renal insufficiency/disease~* peripheral neuropathy of the surgical site~* morbid obesity~* inability to communicate with the investigators and hospital staff~* incarceration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single injection with Saline infused TAP catheter (Type: PLACEBO_COMPARATOR): Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
- Single injection with Ropivicaine infused TAP catheter (Type: ACTIVE_COMPARATOR): Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).